European Companies Search Engine
EU funding (€365,243): Ensuring the future of EUPATI beyond 2020 Hor 1 Sept 2018 EU Research and Innovation programme "Horizon"
Overview
Text
Ensuring the future of EUPATI beyond 2020
The European Patients' Academy on Therapeutic Innovation (EUPATI) IMI project resulted in a number of key outputs for the field of patient engagement. The core activities continue running until 2019 under a PPP consortium under an EPF programme focusing on the Patient Expert Training Course, the multilingual public Toolbox, and the EUPATI National Platforms Network. It is imperative that these pillars that support the patient engagement landscape exist in the medium- and long-term to address the growing field of patient engagement. Further investment is needed to develop sustainable models of collaboration to ensure this, and put into place the infrastructure required for these to work, building on those already established under IMI-EUPATI.
Funded Companies:
| Company name | Funding amount |
| Abbvie Inc. | €0.00 |
| Bayer AG | €0.00 |
| European Aids Treatment Group e. V. | €31,488 |
| European Forum for Good Clinical Practice | €44,476 |
| Forum des Patients Europeens | €188,340 |
| Glaxosmithkline Research & Development Ltd. | €0.00 |
| Irish Platform for Patients' Organisations Science and Industry Ltd. by Guarantee | €97,189 |
| Kobenhavns Universitet | €3,750.00 |
| Novartis Pharma AG | €0.00 |
| Novo Nordisk A/S | €0.00 |
| Pfizer Ltd. | €0.00 |
| UCB Biopharma | €0.00 |
Source: https://cordis.europa.eu/project/id/806995
The filing refers to a past date, and does not necessarily reflect the current state.
